MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-12-2026
Acasti Pharma Revenue 2011-2026 | ACST
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Acasti Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 100 M | 196 K | - | - | - | - | 27.8 K | 216 K | 450 K | 707 K | 127 K | 29 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 100 M | 27.8 K | 12.7 M |
Quarterly Revenue Acasti Pharma
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 81 K | 81 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 81 K | 81 K | 81 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M |  USA |
 |
Agenus
AGEN
|
156 M | $ 3.27 | -1.8 % | $ 1.17 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
54 M | $ 29.33 | -2.98 % | $ 1.7 B | USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Akebia Therapeutics
AKBA
|
236 M | $ 1.26 | -3.44 % | $ 324 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Alector
ALEC
|
21 M | $ 2.26 | -7.2 % | $ 233 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Aligos Therapeutics
ALGS
|
6.19 M | $ 7.02 | -0.21 % | $ 451 M | USA |
 |
Alkermes plc
ALKS
|
1.48 B | $ 29.32 | -2.61 % | $ 4.83 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
95 K | $ 2.57 | -7.73 % | $ 403 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
3.71 B | $ 330.95 | -0.59 % | $ 43.4 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Altimmune
ALT
|
20 K | $ 4.2 | -2.55 % | $ 298 M | USA |
 |
ALX Oncology Holdings
ALXO
|
1.18 M | $ 2.11 | 0.09 % | $ 110 M | USA |
 |
Amgen
AMGN
|
36.8 B | $ 387.85 | 0.03 % | $ 209 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 20.22 | -0.05 % | $ 945 M | USA |
 |
Amarin Corporation plc
AMRN
|
307 M | $ 13.62 | -1.3 % | $ 5.55 B | Irlanda |
 |
AIM ImmunoTech
AIM
|
141 K | $ 0.92 | 5.25 % | $ 44.2 M | USA |
 |
AnaptysBio
ANAB
|
91.3 M | $ 54.61 | -0.8 % | $ 1.55 B | USA |
 |
Anika Therapeutics
ANIK
|
167 M | $ 14.44 | 0.53 % | $ 212 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
614 M | $ 75.31 | 1.91 % | $ 1.45 B | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Apellis Pharmaceuticals
APLS
|
1 B | $ 20.53 | -2.05 % | $ 2.59 B | USA |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.78 | -0.67 % | $ 4.25 M | China |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptevo Therapeutics
APVO
|
3.11 M | $ 7.28 | -0.55 % | $ 2.01 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
Aquestive Therapeutics
AQST
|
57.6 M | $ 3.99 | -0.15 % | $ 346 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
152 M | $ 8.11 | -1.44 % | $ 219 M |  Israel |
 |
Ardelyx
ARDX
|
407 M | $ 6.32 | -3.54 % | $ 1.52 B | USA |
 |
argenx SE
ARGX
|
36.4 M | $ 762.51 | -0.58 % | $ 25 B |  Niderland |